In the present study, a kind of Eu(III) post-functionalized Zr(IV)-based metal-organic framework (UiO-66(COOH) 2 , Zr-MOF: Eu 3+ ) was synthesized and utilized as an independently luminescent probe for sensing bilirubin (BR) in human serum, a biomarker of jaundice hepatitis. It can be served as a turn-off fluorescent switch for BR because its red emission from Eu 3+ can be easily quenched by BR through a fluorescent resonant energy transfer (FRET) process between BR and its ligands, and as a result, BR is recognized successfully. Particularly, Zr-MOF: Eu 3+ has shown many appealing properties, such as high sensitivity, quick response (less than 1 min), broad response window (0–15 μM), and excellent selectivity. Most importantly, a kind of portable test paper based on Zr-MOF: Eu 3+ probe has been developed for directly assessing the level of BR in real human serum and further diagnosing bilirubin-related diseases via visually observing the luminescent color variation.
Kun Yang,Chunlai Wang,Xiaohui Wei,Sheng Ding,Changjun Liu,Feng Tian,Fan Li
The major obstacles to the wider application of photodynamic therapy (PDT) are drawbacks of the current photosensitizers and the tissue penetration limit of the common outer light source. In the present study, the chemiluminescence (CL) from the luminol–H2O2–horseradish peroxidase reaction was explored as a potential inner light source for the intracellular activation of carbon dots (CDs)-based PDT system. To fully use the light and enhance the overall PDT yield, the nanocarrier of CDs, the light of CL, and the PDT agent chlorin e6 (Ce6) were carefully selected and designed to form an efficient and united system. Bright-yellow-emissive CDs (y-CDs) were synthesized through purposeful regulation of the absorption and emission spectra to enhance the overlapping areas in the chemiluminescence resonance energy transfer (CRET) and fluorescence resonance energy transfer (FRET) processes. Our results reflected CL-induced y-CDs-Ce6 system (10 μM) successfully generated reactive oxygen species (ROS, 35.93%), killed ∼90% SMMC-7721 cells in vitro, and significantly delayed tumor growth in vivo. On the basis of immunohistochemical observations of proliferating cell nuclear antigen (PCNA) and platelet/endothelial cell adhesion molecule-1 (PECAM-1 or CD31) results, we concluded that the CL-induced y-CDs-Ce6 system had excellent performance in cancer therapy. The enhanced therapeutic effect was ascribed to two pathways: a direct CRET process and another process of CRET with subsequent y-CD-mediated FRET (CRET-to-FRET).
危险品化学品经营许可证（带存储）